Axitinib
TFE3-Rearranged Renal Cell Carcinoma
National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the TFE3-Rearranged Renal Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bms-907351 Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Phase 2 | B |
Ipilimumab Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Phase 2 | CCC |
Nivolumab National Cancer Institute (NCI) | Phase 2 | CCC |
Same molecule, other indications
Axitinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →